Abstract Number: 0572 • ACR Convergence 2020
Two-year Cost-effectiveness Between Two Gradual Tapering Strategies in Rheumatoid Arthritis: Cost-utility Analysis of the TARA Trial
Background/Purpose: The benefits of tapering are a decreased risk of long-term adverse events and a reduction of health care costs, especially when bDMARDs are tapered.…Abstract Number: 0746 • ACR Convergence 2020
HDL-bound yRNA-derived Small RNAs Are Altered in Patients with Rheumatoid Arthritis
Background/Purpose: Small RNAs (sRNAs), including microRNAs (miRNAs) and yRNA-derived sRNAs (yDRs), are important gene regulators and markers of disease. HDL, while known for its anti-atherogenic…Abstract Number: 0763 • ACR Convergence 2020
Plasmatic Proteome in Individuals with Arthralgia at Risk of Developing Rheumatoid Arthritis
Background/Purpose: The presence of antibodies against citrullinated proteins (ACPA) significantly increases the risk of developing rheumatoid arthritis (RA). EULAR characterised individuals with arthralgia suspicious for…Abstract Number: 0780 • ACR Convergence 2020
Subsets of Synovial Fluid Derived Fibroblast-like Synoviocytes in Rheumatoid Arthritis
Background/Purpose: In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) secrete inflammatory cytokines and chemokines, invade and degrade cartilage, and stimulate osteoclast that cause bone erosion. Recently,…Abstract Number: 0797 • ACR Convergence 2020
Comparison of the Efficacy and Safety of Janus Kinase Inhibitors and DMARDs in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis
Background/Purpose: Janus Kinase (JAK) inhibitors have shown long term benefit in patients with active RA with inadequate response to conventional or biologic DMARDs (1). Due to…Abstract Number: 0813 • ACR Convergence 2020
Treatment Outcomes in Patients with Seropositive versus Seronegative Rheumatoid Arthritis in Czech Registry ATTRA Treated with JAK Inhibitors
Background/Purpose: Seropositivity / seronegativity in RA may have influence on response to bDMARDs or tsDMARDs. There is incomplete knowledge of differences in efficacy of JAK…Abstract Number: 0830 • ACR Convergence 2020
Discontinuation Rate of Tofacitinib Is Similar When Compared to TNF Inhibitors in Rheumatoid Arthritis Patients: Real World Results from a Rheumatoid Arthritis Cohort
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…Abstract Number: 0974 • ACR Convergence 2020
Role of NR4A Nuclear Receptor Family in RA Synovial Ectopic Lymphoid Neogenesis Revealed by Single Cell Profiling
Background/Purpose: Ectopic lymphoid structures (ELS) have been observed in synovial tissue of rheumatoid arthritis (RA) patients but their functional relevance in the disease remains unclear.…Abstract Number: 1011 • ACR Convergence 2020
Effectiveness, Safety and Quality of Life with Tofacitinib Treatment in Adult Patients with Rheumatoid Arthritis Under Routine Clinical Care: First Interim Results from a German Non-Interventional, Prospective, Multi-Center Study
Background/Purpose: Tofacitinib is an orally applied Janus kinase inhibitor, which is approved for rheumatoid arthritis (RA) treatment in the USA since 2012, so that ‘real…Abstract Number: 1182 • ACR Convergence 2020
Increased Prevalence of Carotid Atherosclerosis in Postmenopausal Women with Rheumatoid Arthritis: A Case Control Study
Background/Purpose: Cardiovascular disease (CVD) is the primary cause of mortality in women in developed countries. CVD risk rises with age, yet for women there is…Abstract Number: 1198 • ACR Convergence 2020
Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis
Background/Purpose: Despite the known excess mortality of rheumatoid arthritis-associated interstitial lung disease (RA-ILD), its association with certain lifestyle factors such as obesity and future prediction…Abstract Number: 1214 • ACR Convergence 2020
Association Between Changes in C-reactive Protein at Week 12 and Patient-Reported Outcomes at Week 24 with Sarilumab Therapy Across Three Pivotal Phase 3 Studies
Background/Purpose: Evaluation of response to RA therapy at 12 weeks after initiation is recommended in treatment guidelines. CRP response after 12 weeks of therapy may…Abstract Number: 1232 • ACR Convergence 2020
Association of Low Hemoglobin with Efficacy and Patient-reported Outcomes in Three Phase III Studies of Sarilumab (TARGET, MOBILITY and MONARCH)
Background/Purpose: Anemia is a common comorbidity in patients (pts) with RA, and changes in hemoglobin (Hb) levels are associated with changes in inflammatory disease activity. Since…Abstract Number: 1414 • ACR Convergence 2020
Highly Polyfunctional Metabolically Altered Pathogenic T Cells Accumulate in the Synovial Tissue of RA Patients and Arthralgia Subject but Not Healthy Control Synovial Tissue
Background/Purpose: Effective treatment of Rheumatoid arthritis (RA) patients is achievable within a short window of opportunity following diagnosis. Identification of pathogenic immune mechanisms at a…Abstract Number: 1530 • ACR Convergence 2020
Activin a and Follistatin Alter Endothelial Cell and Rheumatoid Arthritis Synovial Fibroblast Adhesion and Interaction
Background/Purpose: Activin A and follistatin belong to an anti-inflammatory auto-regulatory cycle. Patients with rheumatoid arthritis (RA) have increased activin A levels in the synovial fluid…
- « Previous Page
- 1
- …
- 142
- 143
- 144
- 145
- 146
- …
- 188
- Next Page »